We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
HCM
526
Horan Capital Management
Maryland
$10.3M -$442K -15,174 -4%
SCM
527
Stux Capital Management
New York
$10.2M -$5.35M -183,923 -34%
LTFS
528
Ladenburg Thalmann Financial Services
Florida
$10.2M -$796K -27,356 -7%
UCFA
529
United Capital Financial Advisors
Texas
$10.2M +$1.81M +62,281 +22%
OPCM
530
Osborne Partners Capital Management
California
$10.2M -$105K -3,610 -1%
BFS
531
Bradley Foster & Sargent
Connecticut
$10.2M +$115K +3,950 +1%
HTC
532
Haverford Trust Company
Pennsylvania
$10.1M +$597K +20,513 +6%
BKBG
533
BHF Kleinwort Benson Group
Belgium
$10.1M +$2.59M +88,888 +34%
GT
534
Greenleaf Trust
Michigan
$10.1M -$1.18M -40,566 -10%
BP
535
Banyan Partners
Florida
$10M +$3.45M +118,486 +52%
AA
536
ALPS Advisors
Colorado
$9.98M +$1.57M +54,101 +19%
PWLP
537
Prio Wealth Limited Partnership
Massachusetts
$9.97M -$118K -4,038 -1%
LI
538
LMCG Investments
Massachusetts
$9.89M -$79.4K -2,729 -0.8%
BPB
539
Badgley, Phelps & Bell
Washington
$9.87M +$86.2K +2,962 +0.9%
DIA
540
Davidson Investment Advisors
Montana
$9.85M -$152K -5,218 -2%
Toronto Dominion Bank
541
Toronto Dominion Bank
Ontario, Canada
$9.79M +$3.33M +114,379 +51%
SAM
542
Silvercrest Asset Management
New York
$9.76M -$90.3K -3,102 -0.9%
NB
543
NBT Bank
New York
$9.72M -$63.3K -2,174 -0.6%
GMIM
544
General Motors Investment Management
New York
$9.66M +$465K +15,983 +5%
BONST
545
Bank of Nova Scotia Trust
Ontario, Canada
$9.63M +$211K +7,241 +2%
CTA
546
Chesley Taft & Associates
Illinois
$9.56M +$107K +3,676 +1%
HAI
547
Hennessy Advisors Inc
California
$9.56M +$184K +6,324 +2%
TCM
548
Twin Capital Management
Pennsylvania
$9.52M -$431K -14,809 -4%
SCA
549
Stillwater Capital Advisors
Pennsylvania
$9.52M +$2.21M +75,920 +30%
WCM
550
Windward Capital Management
California
$9.48M -$203K -6,970 -2%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.